Drawing inspiration from SpaceX, Lai Caida, the visionary founder of Jitai Technology, harnesses AI technology to engineer nanomaterials designed to function as drug delivery vectors. These vectors enable the precise administration of medications like mRNA and antibodies. Since its inception in 2020, Jitai Technology has seamlessly integrated AI with experimental methodologies, surmounting the traditional hurdles in formulation development. The company has achieved remarkable success in delivering drugs precisely to vital tissues, including the liver, lungs, muscles, and immune cells. Despite initial challenges with its product pipeline, Jitai Technology has progressively navigated the complexities of drug development by onboarding pharmaceutical industry experts and forging partnerships with leading pharmaceutical companies. This strategic approach has culminated in the establishment of an AI-driven nanodelivery platform. Currently, the company is advancing its commercialization efforts through licensed delivery material patents and proprietary high-value pipelines. Jitai Technology aims to finalize a cohesive human data and business model framework within the next three years, and to elevate delivery precision to the "cellular level" within the next 5 to 7 years. Ultimately, the company aspires to develop groundbreaking new drugs with blockbuster potential.